

File No. SND/MA/22/000094
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(Subsequent New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:

To

M/s. Ajanta Pharma Limited,
Ajanta House, Charkop, Kandivli (West),
Mumbai - 400067.

18/02/2022

18/02/2022

Subject: Permission to conduct Phase III Clinical trial of Loteprednol Etabonate Ophthalmic Suspension 1% w/v - "A Multicentric, Randomized, Double Blind, Double Dummy, Parallel Group, Two Arm, Comparative, Phase III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Loteprednol Etabonate Ophthalmic Suspension 1% w/v of Ajanta Pharma Ltd. versus Loteprednol Etabonate Ophthalmic Suspension 0.5% w/v in the treatment of Post-Operative inflammatory conditions of the Eye". (Protocol No. APL/CT/22/02; Version No.: V02, Date: 20.04.2022) - Reg.

CT NOC No.: CT/SND/009/2022

Sir,

With reference to your Application No. SND/CT21/FF/2022/30700 dated 28-02-2022 please find enclosed herewith the permission in Form CT-06, CT NOC No. **CT/SND/009/2022** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully,

(Dr. V. G. Somani)
Central Licensing Authority

Conditions of Permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site registered with the Central Licencing Authority under rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site.

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site,
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval.
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules.
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier.
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination.
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter.

- (xiii) The premises of the sponsor including his representatives and clinical trial sites shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority.
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) It may kindly be noted that merely granting permission to conduct Clinical trial with the drug does not convey or imply that based on the Clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

**PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG**

CT NOC NO.: CT/SND/009/2022

The Central Licensing Authority hereby permits **M/s Ajanta Pharma Limited, Ajanta House, Charkop, Kandivli (West), Mumbai - 400067** to conduct clinical trial of the new drug or investigational new drug as per Protocol No. **APL/CT/22/02; Version No.: V02, Date: 20.04.2022** in the below mentioned clinical trial sites.

2 Details of new drug or investigational new drug

Names of the new drug:	Loteprednol Etabonate Ophthalmic Suspension 1% w/v
Therapeutic class:	Corticosteroid
Dosage form:	Ophthalmic Suspension
Composition:	Each mL Contains: Loteprednol Etabonate..... 1.0% w/v Benzalkonium Chloride IP.....0.01% w/v (As Preservative) Sterile Aqueous Vehicle.....q.s.
Indications:	It is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Details of clinical trial sites

Sr. No.	Name of Principal Investigator & Trial sites	Ethics Committee Name/ Registration Number
1	Dr. Rajendra Prakash Maurya Department of Ophthalmology, Institute of Medical Sciences, BHU, Varanasi Uttar Pradesh- 221005, India	Institutional Human Ethics Committee Institute of Medical Sciences, BHU, Varanasi, Uttar Pradesh- 221005, India ECR/526/Inst/UP/2014/ RR-20
2	Dr. Shalini Mohan Department of Ophthalmology, GSVM Medical College, Swaroop Nagar, Kanpur- 208002, Uttar Pradesh, India.	Ethics Committee G S V M Medical College, Swaroop Nagar Kanpur- 208002, Uttar Pradesh, India. ECR/680/Inst/UP/2014 /RR-20
3	Dr. Abhishek Vajpeyi Tulsi Hospital India Limited Civil Lines, Kanpur Nagar, Uttar Pradesh - 208001, India	Tulsi Hospital Ethics Committee, Tulsi Hospital India Limited Civil Lines, Kanpur Nagar, Uttar Pradesh - 208001, India ECR/1401/Inst/UP/2020
4	Dr. Attada Tarakeswara Rao, Dr. R. S. P. R. Government Regional Eye Hospital, Resapuvanipalem, Visakhapatnam- 530013, Andhra Pradesh India.	IEC King George hospital, Maharanipeta collector office junction, Visakhapatnam, Andhra Pradesh -530002 India ECR/197/Inst/KGH/20 13/RR-20
5	Dr. P. Seshu Babu, Department of Ophthalmology, Government Medical College & Government General Hospital (Old RIMSGGH) Srikakulam, Andhra Pradesh 532001 India	Institutional Ethics Committee, Government Medical College & Government General Hospital akulam, Andhra Pradesh - 532001 India ECR/492/Inst/AP/2013/ RR-20

6	Dr. Ajay Ambade, Ambade Eye hospital & research center first floor, Kamia Tower, Kamptee Road, Nagpur-40017, Maharashtra, India	Institutional Ethics Committee of Radiance, Hospital Pvt Ltd, and Purohit Nursing Home, JHC RHPNH, 113-A, Qinta Colony, Nagpur-440008, Maharashtra, India. ECR/1560/Inst/MH/2021
7	Dr. Jyotika Mishrikotkar, Department of Clinical Pharmacology and Therapeutics, clinical trial centre MGM Medical college and Hospital, Aurangabad, Maharashtra-431003, India.	MGM Ethics Committee for Research on Human Subject (MGMECRHS) Pharmacology Department, MGM Medical College, N-6, CIDCO, Aurangabad, 431003, Maharashtra, India. ECR/581/Inst/MH/2014/RR-20
8	Dr. P.K. Saraf, Health Point Multispecialty Hospital, 21, Pranath pandit Street, Kolkata-700025, West Bengal, India	Health Point Ethics Committee, 21, Pranath pandit Street, Kolkata-700025, West Bengal, India ECR/284/INST/WB/2013/RR-19
9	Dr. Kali Sankar Das, Regional Institute of Ophthalmology, Medical College and Hospital, Kolkata, 88, College Street Kolkata-700073, West Bengal, India.	Institutional Ethics Committee for Human Research Medical College and hospital, Kolkata 88, College Street Kolkata-700073 West Bengal, India ECR/287/Inst/WB/2013/RR-19
10	Dr. Piyush Jain, ASG Eye Hospital, Plot No.557, Cello Platina Building Near Police Ground, FC Road Pune-411005	Ethics Committee Rao Nursing Home, Rao Nursing Home, Pune- Satara Road, Pune-411037. ECR/597/Inst/MH/2014/RR-20

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940

Place: New Delhi

Date:

11 MAY 2022

(Dr. V. G. Somani)
Central Licensing Authority
Stamp